Skip to main content

Articles

Page 12 of 34

  1. Amyloid-β (Aβ) PET has emerged as clinically useful for more accurate diagnosis of patients with cognitive decline. Aβ deposition is a necessary cause or response to the cellular pathology of Alzheimer’s disea...

    Authors: Ashwin V. Venkataraman, Wenjia Bai, Alex Whittington, James F. Myers, Eugenii A. Rabiner, Anne Lingford-Hughes and Paul M. Matthews
    Citation: Alzheimer's Research & Therapy 2021 13:185
  2. Comprehensive testing of cognitive functioning is standard practice in studies of Alzheimer disease (AD). Short-form tests like the Montreal Cognitive Assessment (MoCA) use a “sampling” of measures, administer...

    Authors: Jason Hassenstab, Jessica Nicosia, Megan LaRose, Andrew J. Aschenbrenner, Brian A. Gordon, Tammie L. S. Benzinger, Chengjie Xiong and John C. Morris
    Citation: Alzheimer's Research & Therapy 2021 13:153
  3. Electrophysiological studies show that reductions in power within the alpha band are associated with the Alzheimer’s disease (AD) continuum. Physical activity (PA) is a protective factor that has proved to red...

    Authors: Jaisalmer de Frutos-Lucas, Pablo Cuesta, Federico Ramírez-Toraño, Alberto Nebreda, Esther Cuadrado-Soto, África Peral-Suárez, David Lopez-Sanz, Ricardo Bruña, Silvia Marcos-de Pedro, María Luisa Delgado-Losada, Ana María López-Sobaler, Inmaculada Concepción Rodríguez-Rojo, Ana Barabash, Juan Manuel Serrano Rodriguez, Simon M. Laws, Alberto Marcos Dolado…
    Citation: Alzheimer's Research & Therapy 2020 12:113
  4. We investigated regional amyloid staging characteristics in 11C-PiB-PET data from middle-aged to older participants at elevated risk for AD enrolled in the Wisconsin Registry for Alzheimer’s Prevention.

    Authors: Fedor Levin, Irina Jelistratova, Tobey J. Betthauser, Ozioma Okonkwo, Sterling C. Johnson, Stefan J. Teipel and Michel J. Grothe
    Citation: Alzheimer's Research & Therapy 2021 13:178
  5. In recent years, mechanistic, epidemiologic, and interventional studies have indicated beneficial effects of omega-3 polyunsaturated fatty acids (n-3 PUFA) against brain aging and age-related cognitive decline...

    Authors: Debora Cutuli, Eugenia Landolfo, Annalisa Nobili, Paola De Bartolo, Stefano Sacchetti, Doriana Chirico, Federica Marini, Luisa Pieroni, Maurizio Ronci, Marcello D’Amelio, Francesca Romana D’Amato, Stefano Farioli-Vecchioli and Laura Petrosini
    Citation: Alzheimer's Research & Therapy 2020 12:150
  6. New therapies are urgently needed for Alzheimer’s disease (AD). Sodium oligomannate (GV-971) is a marine-derived oligosaccharide with a novel proposed mechanism of action. The first phase 3 clinical trial of G...

    Authors: Shifu Xiao, Piu Chan, Tao Wang, Zhen Hong, Shuzhen Wang, Weihong Kuang, Jincai He, Xiaoping Pan, Yuying Zhou, Yong Ji, Luning Wang, Yan Cheng, Ying Peng, Qinyong Ye, Xiaoping Wang, Yuncheng Wu…
    Citation: Alzheimer's Research & Therapy 2021 13:62
  7. Detecting subtle-to-moderate biomarker changes such as those in amyloid PET imaging becomes increasingly relevant in the context of primary and secondary prevention of Alzheimer’s disease (AD). This work aimed...

    Authors: Isadora Lopes Alves, Fiona Heeman, Lyduine E. Collij, Gemma Salvadó, Nelleke Tolboom, Natàlia Vilor-Tejedor, Pawel Markiewicz, Maqsood Yaqub, David Cash, Elizabeth C. Mormino, Philip S. Insel, Ronald Boellaard, Bart N. M. van Berckel, Adriaan A. Lammertsma, Frederik Barkhof and Juan Domingo Gispert
    Citation: Alzheimer's Research & Therapy 2021 13:82
  8. Inflammatory processes have been shown to play a role in dementia. To understand this role, we selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia risk.

    Authors: Danielle Newby, Daniel Prieto-Alhambra, Talita Duarte-Salles, David Ansell, Lars Pedersen, Johan van der Lei, Mees Mosseveld, Peter Rijnbeek, Glen James, Myriam Alexander, Peter Egger, Jana Podhorna, Robert Stewart, Gayan Perera, Paul Avillach, Solène Grosdidier…
    Citation: Alzheimer's Research & Therapy 2020 12:38
  9. Dementia with Lewy bodies (DLB) includes various core clinical features that result in different phenotypes. In addition, Alzheimer’s disease (AD) and cerebrovascular pathologies are common in DLB. All this in...

    Authors: Carla Abdelnour, Daniel Ferreira, Marleen van de Beek, Nira Cedres, Ketil Oppedal, Lena Cavallin, Frédéric Blanc, Olivier Bousiges, Lars-Olof Wahlund, Andrea Pilotto, Alessandro Padovani, Mercè Boada, Javier Pagonabarraga, Jaime Kulisevsky, Dag Aarsland, Afina W. Lemstra…
    Citation: Alzheimer's Research & Therapy 2022 14:14
  10. Increasing evidence supports the use of plasma biomarkers of neurodegeneration and neuroinflammation to screen and diagnose patients with dementia. However, confirmatory studies are required to demonstrate the...

    Authors: Simone Baiardi, Corinne Quadalti, Angela Mammana, Sofia Dellavalle, Corrado Zenesini, Luisa Sambati, Roberta Pantieri, Barbara Polischi, Luciano Romano, Matteo Suffritti, Giuseppe Mario Bentivenga, Vanda Randi, Michelangelo Stanzani-Maserati, Sabina Capellari and Piero Parchi
    Citation: Alzheimer's Research & Therapy 2022 14:153
  11. The extracellular buildup of amyloid beta (Aβ) plaques in the brain is a hallmark of Alzheimer’s disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for identifying and recruiting researc...

    Authors: Abby L. Brand, Paige E. Lawler, James G. Bollinger, Yan Li, Suzanne E. Schindler, Melody Li, Samir Lopez, Vitaliy Ovod, Akinori Nakamura, Leslie M. Shaw, Henrik Zetterberg, Oskar Hansson and Randall J. Bateman
    Citation: Alzheimer's Research & Therapy 2022 14:195
  12. Subjective cognitive decline, perceived worsening of cognitive ability without apparent performance issues on clinical assessment, may be an important precursor to dementia. While previous cross-sectional rese...

    Authors: Raymond P. Viviano and Jessica S. Damoiseaux
    Citation: Alzheimer's Research & Therapy 2021 13:108
  13. Early-onset dementia (EOD, onset age < 65) and late-onset dementia (LOD, onset age ≥ 65) exhibit distinct features. Understanding the risk factors for dementia development and mortality in EOD and LOD respecti...

    Authors: Min Young Chun, Wonjeong Chae, Sang Won Seo, Hyemin Jang, Jihwan Yun, Duk L. Na, Dongwoo Kang, Jungkuk Lee, Dustin B. Hammers, Liana G. Apostolova, Sung-In Jang and Hee Jin Kim
    Citation: Alzheimer's Research & Therapy 2024 16:92
  14. Many families with clinical early-onset Alzheimer’s disease (EOAD) remain genetically unexplained. A combination of genetic factors is not standardly investigated. In addition to monogenic causes, we evaluated...

    Authors: Merel O. Mol, Sven J. van der Lee, Marc Hulsman, Yolande A. L. Pijnenburg, Phillip Scheltens, Harro Seelaar, John C. van Swieten, Laura Donker Kaat, Henne Holstege and Jeroen G. J. van Rooij
    Citation: Alzheimer's Research & Therapy 2022 14:77
  15. Alzheimer’s disease (AD) and frontotemporal dementia (FTD) show network dysfunctions linked with cognitive deficits. Within this framework, network abnormalities between AD and FTD show both convergent and div...

    Authors: Lorenzo Pini, Siemon C de Lange, Francesca Benedetta Pizzini, Ilaria Boscolo Galazzo, Rosa Manenti, Maria Cotelli, Samantha Galluzzi, Maria Sofia Cotelli, Maurizio Corbetta, Martijn P van den Heuvel and Michela Pievani
    Citation: Alzheimer's Research & Therapy 2022 14:199
  16. The retina and brain share many neuronal and vasculature characteristics. We investigated the retinal microvasculature in Alzheimer’s disease (AD) and mild cognitive impairment (MCI) using optical coherence to...

    Authors: Jacqueline Chua, Qinglan Hu, Mengyuan Ke, Bingyao Tan, Jimmy Hong, Xinwen Yao, Saima Hilal, Narayanaswamy Venketasubramanian, Gerhard Garhöfer, Carol Y. Cheung, Tien Yin Wong, Christopher Li-Hsian Chen and Leopold Schmetterer
    Citation: Alzheimer's Research & Therapy 2020 12:161
  17. The amyloid-β42 (Aβ42) peptide plays a crucial role in the pathogenesis of Alzheimer’s disease (AD), the most common neurodegenerative disorder affecting the elderly. Over the past years, several approaches and c...

    Authors: Sabrina Meister, Iavor Zlatev, Julia Stab, Dominic Docter, Sandra Baches, Roland H Stauber, Mordechai Deutsch, Reinhold Schmidt, Stefan Ropele, Manfred Windisch, Klaus Langer, Sylvia Wagner, Hagen von Briesen, Sascha Weggen and Claus U Pietrzik
    Citation: Alzheimer's Research & Therapy 2013 5:51
  18. The differentiation of Lewy body dementia from other common dementia types clinically is difficult, with a considerable number of cases only being found post-mortem. Consequently, there is a clear need for ine...

    Authors: Jack L. Jennings, Luis R. Peraza, Mark Baker, Kai Alter, John-Paul Taylor and Roman Bauer
    Citation: Alzheimer's Research & Therapy 2022 14:109
  19. In view of reported associations between high adiposity, particularly in midlife and late-life dementia risk, we aimed to determine associations between body mass index (BMI), and BMI changes across adulthood ...

    Authors: Christopher A. Lane, Josephine Barnes, Jennifer M. Nicholas, John W. Baker, Carole H. Sudre, David M. Cash, Thomas D. Parker, Ian B. Malone, Kirsty Lu, Sarah-Naomi James, Ashvini Keshavan, Sarah Buchanan, Sarah Keuss, Heidi Murray-Smith, Andrew Wong, Elizabeth Gordon…
    Citation: Alzheimer's Research & Therapy 2021 13:91
  20. The analysis of real-world data in clinical research is rising, but its use to study dementia subtypes has been hardly addressed. We hypothesized that real-world data might be a powerful tool to update AD epid...

    Authors: Anna Ponjoan, Josep Garre-Olmo, Jordi Blanch, Ester Fages, Lia Alves-Cabratosa, Ruth Martí-Lluch, Marc Comas-Cufí, Dídac Parramon, María Garcia-Gil and Rafel Ramos
    Citation: Alzheimer's Research & Therapy 2020 12:60
  21. Alzheimer’s disease (AD) and behavioral variant frontotemporal dementia (bvFTD) cause distinct atrophy and functional disruptions within two major intrinsic brain networks, namely the default network and the s...

    Authors: Adeline Su Lyn Ng, Juan Wang, Kwun Kei Ng, Joanna Su Xian Chong, Xing Qian, Joseph Kai Wei Lim, Yi Jayne Tan, Alisa Cui Wen Yong, Russell Jude Chander, Shahul Hameed, Simon Kang Seng Ting, Nagaendran Kandiah and Juan Helen Zhou
    Citation: Alzheimer's Research & Therapy 2021 13:13
  22. We evaluated Aβ misfolding in combination with Aβ42/40 ratio as a prognostic tool for future clinical progression to mild cognitive impairment (MCI) or dementia due to Alzheimer’s disease (AD) in individuals with...

    Authors: Julia Stockmann, Inge M. W. Verberk, Nina Timmesfeld, Robin Denz, Brian Budde, Julia Lange-Leifhelm, Philip Scheltens, Wiesje M. van der Flier, Andreas Nabers, Charlotte E. Teunissen and Klaus Gerwert
    Citation: Alzheimer's Research & Therapy 2020 12:169

    The Correction to this article has been published in Alzheimer's Research & Therapy 2021 13:25

  23. Subjective cognitive complaints (SCC) have been mostly studied in the context of Alzheimer’s disease in memory clinic settings. The potential of combining SCC with genetic information and blood biomarkers of ...

    Authors: Laura Perna, Hannah Stocker, Lena Burow, Léon Beyer, Kira Trares, Carolin Kurz, Selim Gürsel, Bernd Holleczek, Maia Tatò, Konrad Beyreuther, Ute Mons, Klaus Gerwert, Robert Perneczky, Ben Schöttker and Hermann Brenner
    Citation: Alzheimer's Research & Therapy 2023 15:198
  24. Cognitive impairments, and particularly memory deficits, are a defining feature of the early stages of Alzheimer's disease and vascular dementia. Interventions that target these cognitive deficits and the asso...

    Authors: Alex Bahar-Fuchs, Linda Clare and Bob Woods
    Citation: Alzheimer's Research & Therapy 2013 5:35
  25. Cognitive impairment is an important consequence of stroke and transient ischaemic attack, but its determinants are not fully understood. Simple univariable or multivariable models have not shown clinical util...

    Authors: Bogna A. Drozdowska, Emma Elliott, Martin Taylor-Rowan, Robert C. Shaw, Gillian Cuthbertson, Peter Langhorne and Terence J. Quinn
    Citation: Alzheimer's Research & Therapy 2020 12:85
  26. Measurement of beta-amyloid (Aβ) and phosphorylated tau (p-tau) levels offers the potential for early detection of neurocognitive impairment. Still, the probability of developing a clinical syndrome in the pre...

    Authors: Zsolt Huszár, Marie Anne Engh, Márk Pavlekovics, Tomoya Sato, Yalea Steenkamp, Bernard Hanseeuw, Tamás Terebessy, Zsolt Molnár, Péter Hegyi and Gábor Csukly
    Citation: Alzheimer's Research & Therapy 2024 16:81
  27. Gene expression is dysregulated in Alzheimer’s disease (AD) patients, both in peripheral blood and post mortem brain. We investigated peripheral whole-blood gene (co)expression to determine molecular changes p...

    Authors: Emma S. Luckett, Magdalena Zielonka, Amine Kordjani, Jolien Schaeverbeke, Katarzyna Adamczuk, Steffi De Meyer, Koen Van Laere, Patrick Dupont, Isabelle Cleynen and Rik Vandenberghe
    Citation: Alzheimer's Research & Therapy 2023 15:121
  28. Excessive daytime sleepiness is a commonly reported problem in dementia with Lewy bodies (DLB). We examined the relationship between nighttime sleep continuity and the propensity to fall asleep during the day ...

    Authors: Tanis J Ferman, Glenn E Smith, Dennis W Dickson, Neill R Graff-Radford, Siong-Chi Lin, Zbigniew Wszolek, Jay A Van Gerpen, Ryan Uitti, David S Knopman, Ronald C Petersen, Joseph E Parisi, Michael H Silber and Bradley F Boeve
    Citation: Alzheimer’s Research & Therapy 2014 6:76
  29. Isolated subjective cognitive impairment (SCI) and mild cognitive impairment (MCI) are the prodromal phases of dementia with Lewy bodies (DLB). MEMENTO is a nationwide study of patients with SCI and MCI with c...

    Authors: Frederic Blanc, Vincent Bouteloup, Claire Paquet, Marie Chupin, Florence Pasquier, Audrey Gabelle, Mathieu Ceccaldi, Paulo Loureiro de Sousa, Pierre Krolak-Salmon, Renaud David, Clara Fischer, Jean-François Dartigues, David Wallon, Olivier Moreaud, Mathilde Sauvée, Catherine Belin…
    Citation: Alzheimer's Research & Therapy 2022 14:96
  30. A hallmark of Alzheimer's disease (AD) is the presence of senile plaques composed of aggregated amyloid β (Aβ) peptides. Pathological aging (PA) is a postmortem classification that has been used to describe br...

    Authors: Brenda D Moore, Paramita Chakrabarty, Yona Levites, Tom L Kukar, Ann-Marie Baine, Tina Moroni, Thomas B Ladd, Pritam Das, Dennis W Dickson and Todd E Golde
    Citation: Alzheimer's Research & Therapy 2012 4:18
  31. Novel compounds with potential to attenuate or stop the progression of Alzheimer's disease (AD) from its presymptomatic stage to dementia are being tested in man. The study design commonly used is the long-ter...

    Authors: René Spiegel, Manfred Berres, André R Miserez and Andreas U Monsch
    Citation: Alzheimer's Research & Therapy 2011 3:9
  32. Diagnostic effectiveness of Ioflupane I 123 injection (DaTSCANTM, DaTscanTM, or [123I]FP-CIT or ioflupane [123I]) SPECT imaging, was assessed in patients with clinically uncertain parkinsonian syndrome (CUPS).

    Authors: Nin Bajaj, Robert A Hauser, John Seibyl, Andreas Kupsch, Michail Plotkin, Chris Chen and Igor D Grachev
    Citation: Alzheimer's Research & Therapy 2014 6:67
  33. Until now, Mendelian randomization (MR) studies have investigated the causal association of risk factors with Alzheimer’s disease (AD) using large-scale AD genome-wide association studies (GWAS), GWAS by proxy...

    Authors: Haijie Liu, Yang Hu, Yan Zhang, Haihua Zhang, Shan Gao, Longcai Wang, Tao Wang, Zhifa Han, Bao-liang Sun and Guiyou Liu
    Citation: Alzheimer's Research & Therapy 2022 14:17
  34. The clinical and scientific study of dementia in adults with Down syndrome led to the development of the amyloid hypothesis as a fundamental concept in Alzheimer's disease pathogenesis. The journey started wit...

    Authors: Robyn A Wallace and Arthur J Dalton
    Citation: Alzheimer's Research & Therapy 2011 3:13
  35. The differential diagnosis of frontotemporal dementia (FTD) and Alzheimer’s disease (AD) is difficult due to the overlaps of clinical symptoms. Structural magnetic resonance imaging (sMRI) presents distinct br...

    Authors: Qun Yu, Yingren Mai, Yuting Ruan, Yishan Luo, Lei Zhao, Wenli Fang, Zhiyu Cao, Yi Li, Wang Liao, Songhua Xiao, Vincent C. T. Mok, Lin Shi and Jun Liu
    Citation: Alzheimer's Research & Therapy 2021 13:23
  36. Administration of several cardiovascular drugs has an effect on dementia. We aimed to investigate whether there are differences in the use of cardiovascular medication between different dementia disorders.

    Authors: Pavla Cermakova, Seyed-Mohammad Fereshtehnejad, Kristina Johnell, Bengt Winblad, Maria Eriksdotter and Dorota Religa
    Citation: Alzheimer's Research & Therapy 2014 6:34

    The Erratum to this article has been published in Alzheimer's Research & Therapy 2014 6:63

  37. Disturbances in brain cholesterol homeostasis may be involved in the pathogenesis of Alzheimer’s disease (AD). Lipid-lowering medications could interfere with neurodegenerative processes in AD through choleste...

    Authors: Bojana Petek, Henrike Häbel, Hong Xu, Marta Villa-Lopez, Irena Kalar, Minh Tuan Hoang, Silvia Maioli, Joana B. Pereira, Shayan Mostafaei, Bengt Winblad, Milica Gregoric Kramberger, Maria Eriksdotter and Sara Garcia-Ptacek
    Citation: Alzheimer's Research & Therapy 2023 15:220
  38. Optimization of vascular risk factor control is emerging as an alternative approach to improve cognitive outcomes in Alzheimer’s disease, although its efficacy is still under debate. We aimed to investigate th...

    Authors: Yu-Wen Cheng, Ming-Jang Chiu, Ya-Fang Chen, Ting-Wen Cheng, Ya-Mei Lai and Ta-Fu Chen
    Citation: Alzheimer's Research & Therapy 2020 12:91
  39. Alzheimer’s disease (AD) is caused by many intertwining pathologies involving metabolic aberrations. Patients with metabolic syndrome (MetS) generally show hyperglycemia and dyslipidemia, which can lead to the...

    Authors: Monika Renuka Sanotra, Shu-Huei Kao, Ching-Kuo Lee, Chun-Hsien Hsu, Wen-Chung Huang, Tsuei-Chuan Chang, Fang-Yu Tu, I-Uen Hsu and Yung-Feng Lin
    Citation: Alzheimer's Research & Therapy 2023 15:115
  40. Neuropsychiatric symptoms (NPS) are common in individuals with Alzheimer’s disease (AD) dementia, but substantial heterogeneity exists in the manifestation of NPS. Sex differences may explain this clinical var...

    Authors: Willem S. Eikelboom, Michel Pan, Rik Ossenkoppele, Michiel Coesmans, Jennifer R. Gatchel, Zahinoor Ismail, Krista L. Lanctôt, Corinne E. Fischer, Moyra E. Mortby, Esther van den Berg and Janne M. Papma
    Citation: Alzheimer's Research & Therapy 2022 14:48
  41. To investigate the association of plasma pTau181, assessed with a new immunoassay, with neurodegeneration of white matter and gray matter cross-sectionally and longitudinally, in aging and Alzheimer’s disease.

    Authors: Cécile Tissot, Andréa L. Benedet, Joseph Therriault, Tharick A. Pascoal, Firoza Z. Lussier, Paramita Saha-Chaudhuri, Mira Chamoun, Melissa Savard, Sulantha S. Mathotaarachchi, Gleb Bezgin, Yi-Ting Wang, Jaime Fernandez Arias, Juan Lantero Rodriguez, Anniina Snellman, Nicholas J. Ashton, Thomas K. Karikari…
    Citation: Alzheimer's Research & Therapy 2021 13:69
  42. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is characterized by altered cellular metabolism in the brain. Several of these alterations have been found to be exacerbated in females...

    Authors: Abigail Strefeler, Maxime Jan, Manfredo Quadroni, Tony Teav, Nadia Rosenberg, Jean-Yves Chatton, Nicolas Guex, Hector Gallart-Ayala and Julijana Ivanisevic
    Citation: Alzheimer's Research & Therapy 2023 15:8
  43. Carefully conducted systematic reviews (SRs) can provide reliable evidence on the effectiveness of treatment strategies for Alzheimer’s disease (AD). Nevertheless, the reliability of SR results can be limited ...

    Authors: Claire C. W. Zhong, Jinglun Zhao, Charlene H. L. Wong, Irene X. Y. Wu, Chen Mao, Jerry W. F. Yeung and Vincent C. H. Chung
    Citation: Alzheimer's Research & Therapy 2022 14:159
  44. Previous models of Alzheimer’s disease (AD) progression were primarily hypothetical or based on data originating from single cohort studies. However, cohort datasets are subject to specific inclusion and exclu...

    Authors: Sepehr Golriz Khatami, Yasamin Salimi, Martin Hofmann-Apitius, Neil P. Oxtoby and Colin Birkenbihl
    Citation: Alzheimer's Research & Therapy 2022 14:55
  45. Diagnostic performance of optical coherence tomography (OCT) to detect Alzheimer’s disease (AD) and mild cognitive impairment (MCI) remains limited. We assessed whether compensating the circumpapillary retinal...

    Authors: Jacqueline Chua, Chi Li, Lucius Kang Hua Ho, Damon Wong, Bingyao Tan, Xinwen Yao, Alfred Gan, Florian Schwarzhans, Gerhard Garhöfer, Chelvin C. A. Sng, Saima Hilal, Narayanaswamy Venketasubramanian, Carol Y. Cheung, Georg Fischer, Clemens Vass, Tien Yin Wong…
    Citation: Alzheimer's Research & Therapy 2022 14:41
  46. Memantine and cholinesterase inhibitors potentially offer additional benefits in Alzheimer's disease (AD) when used together. This study assessed the efficacy and safety of combination treatment with memantine...

    Authors: Alireza Atri, José L Molinuevo, Ole Lemming, Yvonne Wirth, Irena Pulte and David Wilkinson
    Citation: Alzheimer's Research & Therapy 2013 5:6
  47. Varoglutamstat (formerly PQ912) is a small molecule that inhibits the activity of the glutaminyl cyclase to reduce the level of pyroglutamate-A-beta (pGluAB42). Recent studies confirm that pGluAB42 is a partic...

    Authors: E. G. B. Vijverberg, T. M. Axelsen, A. R. Bihlet, K. Henriksen, F. Weber, K. Fuchs, J. E. Harrison, K. Kühn-Wache, P. Alexandersen, N. D. Prins and Philip Scheltens
    Citation: Alzheimer's Research & Therapy 2021 13:142
  48. Accumulating evidence suggests that BMI1 confers protective effects against Alzheimer’s disease (AD). However, the mechanism remains elusive. Based on recent pathophysiological evidence, we sought for the first t...

    Authors: Jun Pyo Kim, Bo-Hyun Kim, Paula J. Bice, Sang Won Seo, David A. Bennett, Andrew J. Saykin and Kwangsik Nho
    Citation: Alzheimer's Research & Therapy 2021 13:164

    The Correction to this article has been published in Alzheimer's Research & Therapy 2022 14:13